证券代码：688117 证券简称：圣诺生物 公告编号：2025-036 成都圣诺生物科技股份有限公司 关于召开2025年第一次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 12 月 17 日 至2025 年 12 月 17 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2025年第一次临时股东会 召开日期时间：2025 年 12 月 17 日 14 点 00 分 召开地点：四川省成都市大邑县大安路 98 号成都圣诺生物科技股份有限公 司会议室 （五） 网络投票的系统、起止日期和投票时间。 股东会召开日期：2025年12月17日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 （二） 股东会召集人：董事会 （三） 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 （四） 现场会议召开的日期、时间和 ...

Group 1 - Enjie Co., Ltd. is planning to acquire 100% equity of Zhongke Hualian and will suspend trading from December 1, 2025 [3] - ST Tianrui's controlling shareholder is planning a change in company control, leading to a trading suspension from December 1, 2025, expected to last no more than two trading days [4] - Jiarong Technology intends to raise no more than 1 billion yuan through a private placement and acquire 100% of Hangzhou Lanran [5] Group 2 - Baillie Gifford's subsidiary received a milestone payment of $250 million related to a collaboration agreement with Bristol-Myers Squibb [6] - Jiangxi Copper is planning to acquire shares of the overseas listed company SolGold Plc, with a non-binding cash offer of 26 pence per share [7][8] - China Shenhua's subsidiary successfully completed a 168-hour trial run of the No. 3 unit of the Beihai Phase II project, which is a key energy development project in Guangxi [9] Group 3 - Huayang Co., Ltd. has launched a high-performance carbon fiber project with an annual production capacity of 200 tons [11] - Dameng Data announced the release of its general manager from detention by the local supervisory committee [12] Group 4 - Zhongwei Company plans to reduce its stake by up to 1% through a block trade [13] - Yulide's board members plan to reduce their holdings by no more than 0.0313% of the company's total shares [14] - Saint Noble Bio's executives plan to reduce their holdings by no more than 0.024% of the company's total shares [15] Group 5 - Aoride plans to sign a comprehensive technical service agreement with a total amount of approximately 635 million yuan [16]

Group 1 - Daqian Ecological announced the resignation of Chairman Zhang Yuan due to personal reasons, affecting his roles in the board and strategic committee [1] - Daqian Ecological, established in October 1988, focuses on urban renewal, rural revitalization, and ecological restoration [1] Group 2 - Haili Biological plans to use up to 500 million yuan of idle funds to invest in financial products issued by banks, brokers, trusts, and fund companies [1] - Haili Biological, founded in July 1981, specializes in in vitro diagnostic reagents and oral tissue repair and regeneration materials [1] Group 3 - Xianglou New Materials' application for a private placement of shares has been accepted by the Shenzhen Stock Exchange [2] - Xianglou New Materials, established in December 2005, is engaged in the research, production, and sales of customized precision stamping new materials [3] Group 4 - Zhuochuang Information has submitted an application for H-share listing to the Hong Kong Stock Exchange [4] - Zhuochuang Information, founded in April 2004, provides market data monitoring, trading price evaluation, industry data analysis, and research [4] Group 5 - Zhongwei Company plans to reduce its shareholding by up to 626,150 shares, representing 1% of the total share capital [5] - Zhongwei Company, established in May 2004, focuses on the research, production, and sales of high-end semiconductor equipment and related products [5] Group 6 - Jiarong Technology intends to raise up to 1 billion yuan through a private placement to acquire 100% of Hangzhou Lanran [6] - Jiarong Technology, founded in February 2005, specializes in membrane separation equipment and high-performance membrane components [6] Group 7 - Dameng Data's director and general manager Pi Yu has had his detention lifted by the local supervisory committee [7] - Dameng Data, established in November 2000, provides various database software, cloud computing, big data products, and related technical services [7] Group 8 - Huayang Co. has launched a 200-ton annual production project for high-performance carbon fiber [8] - Huayang Co., founded in December 1999, is involved in coal production, power generation, and renewable energy technologies [8] Group 9 - Saintno Biological's executives plan to collectively reduce their holdings by up to 37,600 shares, which is 0.024% of the total share capital [9] - Saintno Biological, established in July 2001, focuses on the research, production, and sales of peptide raw materials and formulations [9] Group 10 - *ST Dongyi is in the process of signing a comprehensive technical service agreement worth 635 million yuan [10] - *ST Dongyi, founded in November 1996, provides comprehensive home decoration services [11] Group 11 - Jiangxi Copper is attempting to acquire all shares of London-listed SolGold, with a recent offer of 26 pence per share [12] - Jiangxi Copper, established in January 1997, specializes in copper and gold mining, smelting, and processing [12] Group 12 - China Shenhua's subsidiary has successfully completed a 168-hour trial run of its power generation unit [13] - China Shenhua, founded in November 2004, is involved in coal and electricity production and sales [13] Group 13 - Baile Tianheng's subsidiary has received a milestone payment of 250 million USD from BMS [14] - Baile Tianheng, established in August 2006, focuses on innovative biopharmaceuticals and chemical preparations [14] Group 14 - Yulide's directors plan to reduce their holdings by up to 35,000 shares, representing 0.0313% of the total share capital [15] - Yulide, founded in December 2003, specializes in the research, production, and sales of testing and measuring instruments [15] Group 15 - Aters plans to establish joint ventures with its controlling shareholder to adjust its U.S. market operations [15] - Aters, established in April 2006, focuses on lithium-ion battery separator products and sterile packaging [15] Group 16 - Enjie Co. is planning to acquire 100% of Zhongke Hualian's shares, leading to a stock suspension [16] - Enjie Co., founded in April 2006, specializes in lithium-ion battery separator products and sterile packaging [16] Group 17 - ST Tianrui's controlling shareholder is planning a change in company control, resulting in a stock suspension [16] - ST Tianrui, established in July 2006, focuses on analytical testing instruments and environmental governance [17]

Group 1 - SystImmune, a subsidiary of BaiLi TianHeng, received a milestone payment of $250 million from Bristol-Myers Squibb, with potential future payments totaling up to $2.5 billion and additional payments of up to $7.1 billion based on specific development, registration, and sales milestones [1] - The milestone payment is expected to significantly enhance cash flow and support research and development efforts, serving as a benchmark case for domestic innovative drugs going global [1] Group 2 - Sanofi Biologics announced that two executives plan to reduce their holdings by up to 18,800 shares each, representing 0.012% of the company's total share capital, due to personal financial needs [2] - The combined share reduction is minimal and is not expected to have a significant direct impact on the market, reflecting a common phenomenon in the A-share market [2] Group 3 - Maiwei Biotech's innovative drug 9MW1911 has completed Phase IIa clinical trials in patients with moderate to severe chronic obstructive pulmonary disease (COPD), showing good safety and tolerability across all dosage groups [3] - The annual incidence of acute exacerbations of COPD decreased by over 30% compared to the placebo group at the recommended dose for Phase IIb studies, with a significant reduction in the proportion of patients experiencing severe exacerbations [3] - These results lay a solid foundation for the Phase IIb study, potentially providing new treatment options for the large COPD patient population and showcasing the R&D capabilities and market potential of domestic innovative drugs in respiratory diseases [3] Group 4 - Novartis announced that the FDA has approved Onasemnogene abeparvovec (Itvisma) for treating spinal muscular atrophy (SMA) in patients aged two and older with confirmed SMN1 gene mutations, making it the first and only gene therapy for this broad population [4] - The unique aspect of this drug is its one-time fixed-dose administration, which does not require adjustments based on age or weight, potentially changing the disease progression fundamentally and alleviating the burden of long-term medication [4] Group 5 - Novo Nordisk has submitted a supplemental new drug application to the FDA for a 7.2 mg dose of semaglutide injection, aimed at controlling long-term weight in obese adults in conjunction with a low-calorie diet and increased physical activity [5] - This move is expected to strengthen Novo Nordisk's leading position in the GLP-1 market and provide better treatment options for obese adults [5]

● 部分董事、高级管理人员持有股份的基本情况 截至本公告披露日，成都圣诺生物科技股份有限公司（以下简称"公司"）副总经理马中刚先生持有公司 股份175,616股，占公司总股本的0.1116%。其中，通过员工持股平台海南圣诺企业管理中心（有限合 伙）（以下简称"圣诺管理"）间接持有公司股份156,800股，来源于公司首次公开发行前取得的股份， 已于2024年6月3日起上市流通；18,816股来源于公司2023年限制性股票激励计划授予取得的股份，已于 2024年12月17日起上市流通。公司董事、副总经理、财务负责人伍利先生持有公司股份116,816股，占 公司总股本的0.0742%。其中，通过员工持股平台圣诺管理间接持有公司股份98,000股，来源于公司首 次公开发行前取得的股份，已于2024年6月3日起上市流通；18,816股来源于公司2023年限制性股票激励 计划授予取得的股份，已于2024年12月17日起上市流通。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688117 证券简称：圣诺生物 公告编号：2025-034 成都圣诺生物科技股份有限公司 部分董事、高级管理人员减持股份计划公告 本 ...

Major Events - Enjie Co., Ltd. is planning to acquire 100% equity of Zhongke Hualian and will suspend trading starting December 1, 2025 due to uncertainties surrounding the transaction [4] - ST Tianrui's controlling shareholder is planning a change in company control, leading to a trading suspension starting December 1, 2025, expected to last no more than two trading days [5] - Jiarong Technology intends to raise no more than 1 billion yuan through a private placement and acquire 100% of Hangzhou Lanran [6][7] - Baili Tianheng's wholly-owned subsidiary received a milestone payment of 250 million USD from BMS related to a collaboration agreement [8] - Jiangxi Copper is planning to acquire shares of the overseas listed company SolGold Plc, with a non-binding cash offer of 26 pence per share, currently in the informal offer stage [9] - China Shenhua's subsidiary successfully completed a 168-hour trial run of its power generation unit, marking a significant milestone in its expansion project [10] - ST Dongyi faces the risk of bankruptcy due to unsuccessful restructuring efforts, which could lead to stock delisting [11] - Huayang Co., Ltd. has launched a high-performance carbon fiber project with an annual production capacity of 200 tons, applicable in various high-tech fields [12] - Dameng Data's general manager has had his detention lifted by the local authorities [13] Shareholding Changes - Zhongwei Company plans to reduce its stake by no more than 1% through block trading, equating to approximately 6.26 million shares [14] - Yulide's directors plan to collectively reduce their holdings by no more than 0.0313%, totaling up to 35,000 shares [15] - Shengnuo Bio's vice president and a board member plan to reduce their holdings by no more than 0.024%, totaling up to 37,600 shares [16] Major Contracts - Aoride plans to sign a comprehensive technical service agreement with Company X, with a total contract value of approximately 635 million yuan [17]

Core Viewpoint - Several companies are undergoing significant corporate actions, including acquisitions, capital raising, and operational milestones, which may present investment opportunities and market implications. Group 1: Corporate Actions - Enjie Co., Ltd. is planning to acquire 100% equity of Zhongke Hualian and will suspend trading starting December 1, 2025 due to uncertainties surrounding the transaction [3] - ST Tianrui's controlling shareholder is planning a change in company control, leading to a trading suspension from December 1, 2025, expected to last no more than two trading days [4] - Jiarong Technology intends to raise up to 1 billion yuan through a private placement and acquire 100% of Hangzhou Lanran, with the transaction making the latter a wholly-owned subsidiary [5] - Jiangxi Copper is in the process of making non-binding cash offers to acquire shares of SolGold Plc at 26 pence per share, currently holding 12.19% of the company [7] Group 2: Financial Milestones - Baillie Gifford's subsidiary SystImmune received a milestone payment of $250 million from Bristol-Myers Squibb related to a collaboration agreement, with potential future payments totaling up to $7.1 billion [6] Group 3: Operational Developments - China Shenhua's subsidiary successfully completed a 168-hour trial run of its 3rd unit at the Beihai Phase II project, which is a key energy development project in Guangxi [8] - Huayang Co., Ltd. has launched a 200-ton annual production project for high-performance carbon fiber, which is expected to serve various high-tech industries [11] Group 4: Shareholder Actions - Zhongwei Company’s major shareholder plans to reduce its stake by up to 1% through block trading [14] - Yulide's directors plan to collectively reduce their holdings by no more than 0.0313% of the company's total shares [15] - Saint Noble Bio's executives plan to reduce their holdings by no more than 0.024% of the company's total shares [16] Group 5: Contracts and Agreements - Aoride plans to sign a comprehensive technical service agreement with Company X, with a total contract value of approximately 635 million yuan [18]

Core Viewpoint - The announcement from Shengnuo Biotech (688117) indicates that two executives plan to reduce their shareholdings due to personal financial needs [1] Summary by Relevant Sections - **Shareholding Reduction Plan** - Vice General Manager Ma Zhonggang and Financial Responsible Officer Wu Li intend to reduce their holdings through centralized bidding or block trading [1] - Ma Zhonggang plans to reduce up to 18,800 shares, representing no more than 0.012% of the company's total share capital [1] - Wu Li also plans to reduce up to 18,800 shares, similarly representing no more than 0.012% of the company's total share capital [1]

Core Viewpoint - The company announced that two executives plan to reduce their shareholdings due to personal financial needs, which may impact investor sentiment and stock performance [1] Summary by Relevant Sections Executive Shareholding Reduction - The company's Vice President, Ma Zhonggang, and the Director, Vice President, and Chief Financial Officer, Wu Li, intend to reduce their holdings through centralized bidding or block trading [1] - Ma Zhonggang plans to reduce up to 18,816 shares, representing no more than 0.0120% of the company's total share capital [1] - Wu Li also plans to reduce up to 18,816 shares, similarly representing no more than 0.0120% of the company's total share capital [1] Timeline and Compliance - The reduction period is set to begin 15 trading days after the announcement, lasting from December 23, 2025, to March 22, 2026 [1] - The shares to be reduced are sourced from equity incentives, and the implementation of the reduction plan will strictly adhere to relevant laws and regulations [1]

人民财讯11月30日电，圣诺生物(688117)11月30日公告，公司副总经理马中刚以及董事、副总经理、财 务负责人伍利计划合计减持公司股份不超过3.76万股，即不超过公司总股本的0.024%。 ...